A5066340882- Virus-based gene therapy research
- CAR-T cell therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer Research and Treatments
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Sarcoma Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Nonmelanoma Skin Cancer Studies
- Neuroblastoma Research and Treatments
- Cancer Treatment and Pharmacology
- Multiple and Secondary Primary Cancers
- Cancer, Stress, Anesthesia, and Immune Response
- Multiple Myeloma Research and Treatments
- Occupational and environmental lung diseases
- Glioma Diagnosis and Treatment
- Cancer and Skin Lesions
- Chronic Lymphocytic Leukemia Research
- Cutaneous lymphoproliferative disorders research
- Cancer Diagnosis and Treatment
Sanofi (Finland)
2022-2023
Oncos Therapeutics (Finland)
2013-2017
University of Helsinki
2015-2017
Targovax (Finland)
2017
MSD (Finland)
2016
MSD K.K. (Japan)
2016
We conducted a phase I study with granulocyte macrophage colony stimulating factor (GMCSF)-expressing oncolytic adenovirus, ONCOS-102, in patients solid tumors refractory to available treatments. The objectives of the were determine optimal dose for further use and assess safety, tolerability adverse event (AE) profile ONCOS-102. Further, response rate overall survival evaluated as well preliminary evidence disease control. As an exploratory endpoint, effect ONCOS 102 on biological...
Despite originating from several different tissues, soft-tissue sarcomas (STS) are often grouped together as they share mesenchymal origin and treatment guidelines. Also, with some exceptions, a common denominator is that when the tumor cannot be cured surgery, efficacy of current therapies poor new modalities thus needed. We have studied combination capsid-modified oncolytic adenovirus CGTG-102 (Ad5/3-D24-GMCSF) doxorubicin, or without ifosfamide, preferred first-line chemotherapeutic...
Adenoviruses are excellent immunotherapeutic agents with a unique ability to prime and boost immune responses. Recombinant adenoviruses cause immunogenic cancer cell death subsequent release of tumor antigens for antigen presenting cells, resulting in the priming potent tumor-specific immunity. This effect may be further enhanced by immune-stimulating transgenes expressed virus. We report case 38-year-old female Stage 3 metastatic micropapillary serous carcinoma ovary. She was treated Phase...
Malignant mesothelioma (MM) is a rare cancer type caused mainly by asbestos exposure. The median overall survival time of patient less than 1‐year from diagnosis. Currently there are no curative treatment modalities for malignant mesothelioma, however treatments such as surgery, chemotherapy and radiotherapy can help to improve prognosis increase life expectancy. Pemetrexed‐Cisplatin the only standard care (SoC) but PFS/OS (progression‐free survival/overall survival) initiation up 12 months....
Metastatic melanoma is refractory to irradiation and chemotherapy, but amenable immunological approaches such as immune‐checkpoint‐inhibiting antibodies or adoptive cell therapies. Oncolytic virus replication an immunogenic phenomenon, viruses can be armed with immunostimulatory molecules. Therefore, oncolytic immuno‐virotherapy of malignant appealing approach, which was recently validated by a positive phase 3 trial. We investigated the potency adenovirus Ad5/3‐D24‐GMCSF on panel lines...
Late stage cancer is often associated with reduced immune recognition and a highly immunosuppressive tumor microenvironment. The presence of infiltrating lymphocytes (TILs) specific gene-signatures prior to treatment are linked good prognosis, while the opposite true for extensive immunosuppression. use adenoviruses as vaccines form active immunotherapy initialise tumor-specific response that targets patient's unique antigen repertoire. We report case 68-year-old male asbestos-related...
Sarcomas are a relatively rare cancer, but often incurable at the late metastatic stage. Oncolytic immunotherapy has gained attention over past years, and wide range of oncolytic viruses have been delivered via intratumoral injection with positive safety promising efficacy data. Here, we report preclinical clinical results from treatment sarcoma adenovirus Ad5/3-D24-GMCSF (CGTG-102). is serotype chimeric coding for human granulocyte-macrophage colony-stimulating factor (GM-CSF). The was...
The purpose of this work was to carry out preclinical toxicity and bio-distribution studies required for regulatory approval a clinical trial application Phase I ONCOS-102 (Ad5/3-D24-GM-CSF) therapy advanced cancers (NCT01598129). study design, route administration dosage differs from the protocol in more detail, investigate toxicological profile treatment animal model. carried 300 hamsters divided into nine test groups–three groups six analysis toxicity. Hamsters received by intracardial,...
Breast cancer is a heterogeneous disease, characterized by several distinct biological subtypes, among which triple-negative breast (TNBC) one associated with poor prognosis. Oncolytic virus replication an immunogenic phenomenon, and viruses can be armed immunostimulatory molecules to boost triggered antitumoral immune responses. Cyclophosphamide (CP) chemotherapy drug that cytotoxicity immunosuppression at higher doses, whereas anti-angiogenic properties are observed low continuous dosage....
Vaccination with dendritic cells (DCs), the most potent professional antigen-presenting in body, is a promising approach cancer immunotherapy. However, tumors induce immunosuppression their microenvironment that suppresses and impairs function of DCs. Therefore, human clinical trials DC therapy have often been disappointing. To improve therapeutic efficacy to overcome major obstacles therapy, we generated novel adenovirus, Ad3-hTERT-CMV-hCD40L, which fully serotype 3 expresses hCD40L for...
In clinical trials with oncolytic adenoviruses, there has been no mortality associated treatment vectors. Likewise, in the Advanced Therapy Access Program (ATAP), where 290 patients were treated 10 different viruses, vector-related was observed. However, as patient population who received adenovirus treatments ATAP represented heavily pretreated patients, often very advanced disease, some died relatively soon after receiving their virus mandating autopsy to investigate cause of death. Eleven...
Despite many clinical trials conducted with oncolytic viruses, the exact tumor-level mechanisms affecting therapeutic efficacy have not been established. Currently there are no biomarkers available that would predict outcome to any virus. To assess baseline immunological phenotype and find potential prognostic biomarkers, we monitored mRNA expression levels in 31 tumor biopsy or fluid samples from 27 patients treated adenovirus. Additionally, protein was studied 19 biopsies using...
Background: The rapid development of multiple myeloma (MM) management underscores the value real-world data. In our study we examined 509 adult MM patients treated with immunochemotherapy (ICT) with/without stem cell transplantation (SCT) from 2013 to 2019 in Hospital District Helsinki and Uusimaa, Finland. Materials & methods: Our was based on computational analyses data integrated into hospital lake. Results: After 2017, treatment pattern diversity increased improved access novel...
Malignant mesothelioma is a rare cancer type with no effective treatment therapies so far. Most of the cases are caused due to asbestos exposure. The median survival time patient short, around one year from diagnosis and conventional treatments such as surgery, chemotherapy radiotherapy can help only improve prognosis finally increase patient's life expectancy. Unfortunately, currently there cure for mesothelioma, new strategies against in high demand. ONCOS-102 double targeted, chimeric...
Most cases of keratinocyte cancer can be treated effectively with surgery. However, survival is reduced in patients advanced disease. This retrospective cohort study evaluated overall invasive cancers, and high-risk features for progression the disease mortality Finnish a real-world setting. A total 43,143 types basal cell carcinoma 10,380 cutaneous squamous were identified nationwide. More detailed patient records available subset (basal n = 5,020 1,482) from regional database. Fifty...
Meeting abstracts Advanced tumors are often immunosuppressive. Intratumoral administration of adenovirus activates Toll-like receptor signalling leading to production pro-inflammatory cytokines and activation the innate immune system. Oncolytic causes immunogenic cancer cell death
Abstract Metastatic melanoma is refractory to irradiation and chemotherapy, but amenable immunological approaches such as ipilimumab or adoptive cell therapies. Oncolytic virus replication an immunogenic phenomenon, viruses can be armed with immunostimulatory molecules. Therefore, oncolytic immuno-virotherapy of malignant appealing approach, which was recently validated by a positive phase 3 trial. We investigated the potency adenovirus Ad5/3-D24-GMCSF on panel lines animal models in...
INTRODUCTION: ONCOS-102 is a serotype 5 adenovirus, comprising chimeric capsid for enhanced gene delivery to cancer cells and 24 bp deletion in Rb binding site of E1A region cell restricted replication. armed with granulocyte-macrophage colony-stimulating factor (GM-CSF) an immunostimulatory effect. treatment promising immunotherapy strategy advanced by directly recruiting antigen presenting (APC) at tumor leading induction adaptive tumor-specific CD8+ T response. It's immunological activity...